Okay, let's tackle this question about Cetuximab and Rituximab. The user wants to know what these two drugs are, and they've provided the correct answer as monoclonal antibodies.

First, the core concept here is that both Cetuximab and Rituximab are monoclonal antibodies used in cancer treatment. Monoclonal antibodies are laboratory-produced molecules engineered to target specific antigens on cancer cells. Cetuximab targets the epidermal growth factor receptor (EGFR), which is overexpressed in some cancers like colorectal and head and neck cancers. Rituximab targets CD20, a protein found on the surface of B-cells, used in lymphomas and leukemias.

Now, why is the correct answer monoclonal antibodies? Because both are designed to bind to specific antigens. Cetuximab is a chimeric IgG1 antibody against EGFR, inhibiting tumor growth by blocking signaling pathways. Rituximab is a chimeric IgG1 against CD20, leading to B-cell depletion via complement-mediated lysis and antibody-dependent cell-mediated cytotoxicity.

For the wrong options: If the options were other classes like chemotherapeutics, tyrosine kinase inhibitors, or something else, each would be incorrect. For example, if an option said "chemotherapeutic agents," that's wrong because they're targeted therapies, not traditional chemo. If another option was "tyrosine kinase inhibitors," those are small molecules (like imatinib) that inhibit intracellular enzymes, not antibodies. Another might be "immunomodulators," which are different as they modulate the immune system rather than directly targeting antigens.

The clinical pearl here is to remember the targets: Cetuximab for EGFR and Rituximab for CD20. Also, note that monoclonal antibodies are part of targeted therapy, distinct from conventional chemotherapy. This distinction is crucial for exams.

Putting it all together, the correct answer is monoclonal antibodies. The explanation should cover their specific targets, mechanisms, and differentiate them from other drug classes. Make sure each section is concise and hits the key points without being too wordy.

**Core Concept**
Cetuximab and rituximab are **monoclonal antibodies** used in cancer therapy. They target specific cell surface proteins (EGFR for cetuximab; CD20 for rituximab) to inhibit tumor growth or induce immune-mediated cell death.

**Why the Correct Answer is Right**
Cetuximab binds to the **epidermal growth factor receptor (EGFR)** on epithelial tumors, blocking downstream signaling pathways (e.g., MAPK/ERK) that promote cell proliferation. Rituximab targets **CD20 antigen** on B-cells, triggering complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Both act via antigen-specific immune responses and are classified as monoclonal antibodies (mAbs).

**Why Each Wrong Option is Incorrect**
**Option A:** *Chemotherapeutic agents*—Incorrect. These drugs are targeted therapies, not traditional cytotoxic chemotherapies.
**Option B:** *Tyrosine kinase inhibitors*—Incorrect. These are small molecules (e.g., imatinib) that inhibit intracellular enzymes, not antibodies

✓ Correct Answer: C. Chimeric monoclonal antibodies